贝瑞和康品牌怎么样 申请店铺

外推网助力贝瑞和康品牌出海！通过在本页面挂载贝瑞和康品牌的产品链接和联系邮箱，可以提高贝瑞和康产品曝光！跨境电商爆单神器，目前只要100元/年哦~

北京贝瑞和康生物技术有限公司成立于2010年5月，是专注应用高通量基因测序技术，为临床医学疾病筛查和诊断提供整体解决方案的研发型生物科技公司。

在生物医药晋升为“国家战略性新兴产业”的行业背景下，贝瑞基因凭借自主研发的核心技术，将人类基因组测序技术实践于临床检测。在先天性遗传疾病筛查和诊断领域，贝瑞基因开发出具有全套自主知识产权的贝比安“DNA产前检测”技术（简称贝比安），实现了胎儿染色体疾病的产前检测。随后，可用于婚前孕前、产前及遗传疾病先证者的科诺安染色体疾病检测（简称科诺安）、可用于辅助生殖技术中胚胎植入前染色体数目及结构异常的科孕安胚胎植入前遗传学筛查（简称科孕安）检测相继问世，进一步丰富完善了遗传病筛查与诊断的检测技术体系。在此基础上，贝瑞和康又先后研制开发出针对胎儿染色体微缺失微重复和胎儿单基因疾病基因分型的检测技术，以期实现安全、全覆盖的临床遗传疾病筛查与诊断模式。

在向遗传病筛查与诊断领域不断深入的同时，贝瑞基因在肿瘤分子诊断领域成功推出了基于高通量测序技术的昂科益（Onconi）肿瘤分子诊断产品，涉及靶向用药检测、疗效监测、用药监测、肿瘤易感性检测、肿瘤个体化医疗检测，实现肿瘤分子检测的整体覆盖。其中以具有自主知识产权的cSMART技术为核心的肿瘤基因检测为临床开启了模式。此外，贝瑞基因在产前检测、孕前检测、遗传病检测以及肿瘤检测领域累积的数据，已构建为具有中国人群特色的基因组大数据库。通过与贝勒医学院、阿里云等机构合作，贝瑞基因未来将借助云存储与云计算平台，实现基因组数据简化的终端应用和实时共享。

至此，贝瑞基因形成了从染色体数目和结构水平、染色体微缺失微重复水平、基因水平的技术维度层层深入；从婚前、孕前、产前、新生儿、癌症的产品维度渐次覆盖；从单个个体基因组数据解读到群体基因组数据分析，再到指导性个体基因组数据解读的数字化维度逐级递进的三维立体发展结构。

Beijing Beirui Hekang Biotechnology Co., Ltd. was founded in May 2010. It is a R & D biotechnology company that focuses on the application of high-throughput gene sequencing technology to provide overall solutions for clinical medical disease screening and diagnosis. Under the background of the promotion of biomedical industry to "national strategic emerging industry", berry gene, relying on the core technology of independent research and development, practices the human genome sequencing technology in clinical detection. In the field of screening and diagnosis of congenital genetic diseases, Berea gene has developed a complete set of bebian "DNA prenatal testing" technology (bebian for short) with independent intellectual property rights, which realizes the prenatal testing of fetal chromosomal diseases. Subsequently, konoan chromosomal disease detection (konoan for short) which can be used in premarital pregnancy, prenatal and genetic disease proband, and konoan genetic screening (konoan for short) which can be used in the number and structure of pre implantation chromosomes in the assisted reproductive technology, have come out successively, further enriching and improving the detection technology system of genetic disease screening and diagnosis 。 On this basis, berry and Kang have developed the detection technology for fetal chromosome microdeletion and microduplication and fetal single gene disease genotyping, in order to achieve a safe and full coverage of clinical genetic disease screening and diagnosis mode. In the field of genetic disease screening and diagnosis, berry gene has successfully launched onconi tumor molecular diagnosis products based on high-throughput sequencing technology in the field of tumor molecular diagnosis, involving targeted drug testing, efficacy monitoring, drug monitoring, tumor susceptibility testing, tumor individualized medical testing, to achieve the overall coverage of tumor molecular testing. Among them, the tumor gene detection, which is based on the smart technology with independent intellectual property rights, has opened a model for clinical practice. In addition, the data accumulated in the fields of prenatal test, pre pregnancy test, genetic disease test and tumor test of berry gene have been constructed into a large genome database with Chinese characteristics. Through cooperation with Baylor Medical College, Alibaba cloud and other institutions, Bayley gene will use cloud storage and cloud computing platform to realize terminal application and real-time sharing of genome data simplification in the future. So far, berry gene has formed a digital dimension from chromosome number and structure level, chromosome microdeletion and microduplication level, gene level; from premarital, pre pregnancy, prenatal, newborn, cancer product dimensions gradually covered; from single individual genome data interpretation to group genome data analysis to guiding individual genome data interpretation The three-dimensional development structure of degree progressive.

本文链接： https://brand.waitui.com/b653685ec.html 联系电话：请联系客服添加